420
Participants
Start Date
December 19, 2020
Primary Completion Date
April 15, 2022
Study Completion Date
April 15, 2022
H5N1 antigen combined with MF59 adjuvant
Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
60802- Philippine General Hospital, Manila
60803- Philippine General Hospital - Pediatrics, Manila
60801- Philippine General Hospital - Pediatrics, Manila
60804 - University of Perpetual Help Dalta Medical Center, Las Piñas
60805 - De La Salle Medical and Health Sciences Institute, Dasmariñas
23302- Al Mare Perearstikeskus OÜ, Tallinn
23301- Clinical Research Center, Tartu
Seqirus
INDUSTRY